ALISO VIEJO, Calif. & WILMINGTON, Mass. -- (BUSINESS WIRE) -- Ambry Genetics and Kapa Biosystems announced today that Ambry Genetics has selected the KAPA Hyper Prep Kits for its new ExomeNext and ExomeNext – Rapid tests, comprehensive exome sequencing assays that are designed specifically for establishing neonatal, pediatric and adult-onset diagnoses. Compared to traditional library preparation methods, the KAPA kits feature improved library yields (up to 40 percent of input DNA converted to adapter-ligated library), greater coverage uniformity and a streamlined workflow that only requires 35 minutes of hands-on time and less than three hours of total workflow time.
Whole exome sequencing has successfully been used to identify both inherited and de novo explanatory gene mutations in a diverse variety of autosomal dominant, autosomal recessive and X-linked disorders. In fact, the three Centers for Mendelian Genetics funded by the National Human Genome Research Center have used exome sequencing to recently identify novel genes causative of more than 200 disorders.
“Ambry was the first laboratory to offer clinical whole exome sequencing and has since optimized all components of the test to help achieve the highest diagnostic yield on the market,” said Aaron Elliott, Ph.D., Vice President of Research and Development at Ambry Genetics. “Ambry is committed to partnering with proven industry leaders like Kapa Biosystems to ensure our customers receive the highest quality genetic tests available. The KAPA Hyper Prep Kits add clear value to our tests with improved molecular complexity, sensitivity and coverage uniformity.”
ExomeNext and ExomeNext – Rapid are complex genetic tests that sequence and analyze the protein coding regions or exons of all ~20,000 genes in the human genome in addition to sequencing and screening for characterized mutations in the mitochondrial genome (mtDNA). They are two of the most comprehensive tests available for identifying the underlying genetic cause of a patient’s medical condition in a time and cost-effective manner. The KAPA Hyper Prep Kit features optimally formulated and evolved enzymes that enable higher yields of adapter-ligated library, more uniform coverage and lower amplification bias. The higher quality libraries and simple workflow enable researchers to discover more actionable mutations faster than before. For more information on the ExomeNext tests, please visit: http://www.ambrygen.com/exomenext.
“Ambry’s ExomeNext Test is transforming how we diagnose heterogeneous disorders,” said Brian Komorous, Marketing Director at Kapa Biosystems. “The KAPA Hyper Prep Kit is a versatile, streamlined solution for DNA library preparation for a wide range of applications, including whole exome sequencing, enabling partners like Ambry Genetics to achieve higher quality libraries in less than three hours.”
About Kapa Biosystems
Kapa Biosystems is a life science reagents supplier that employs proprietary, directed evolution technologies to optimize enzymes for PCR, real-time PCR, next-generation sequencing and molecular diagnostic applications. Kapa Biosystems offers a portfolio of best-in-class products containing novel enzymes that confer significant performance advantages when compared to traditional wild-type enzymes. The company is based in Wilmington, Massachusetts with a research, development and manufacturing facility in Cape Town, South Africa. For more information, please visit www.kapabiosystems.com.
About Ambry Genetics
Ambry Genetics is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified commercial clinical laboratory with headquarters in Orange County, California. Since its founding in 1999, it has become a leader in providing genetic services focused on clinical diagnostics and genomic services, particularly in sequencing and array services. Ambry has established a reputation for unparalleled service and for over a decade has been at the forefront of applying new technologies to the clinical molecular diagnostics market and to the advancement of disease research. To learn more about testing and services available through Ambry, please visit www.ambrygen.com.
KAPA is a trademark of Kapa Biosystems. Kapa Biosystems’ products are for Research Use Only; not for use in diagnostic procedures.
All other product names and trademarks are the property of their respective owners.